Does metabolic syndrome mitigate weight loss in overweight Mexican American women treated for 1-year with orlistat and lifestyle modification?
- 37 Downloads
Aims To investigate the effects of a pharmacotherapy (orlistat) plus lifestyle management (OLM) intervention on weight loss in Mexican American women with and without metabolic syndrome (MS). Methods: One hundred and seven female participants aged 21–65 years and of Mexican origin were randomized to either OLM or a wait-list control group (WLC) for one year. The lifestyle interventions were tailored to exhibit features of the Mexican culture. Within each group, subjects with MS were compared to those without MS to assess whether its presence mitigates weight loss. Risk factors for MS also were assessed. Results: Participants with MS in the OLM group experienced significant decreases in weight and body mass index (BMI) as compared to participants without MS. Participants with MS in the OLM group and who completed the study lost 9.3±7.5 kg (20.5±16.5 lb) as compared to participants with MS in the WLC group, who only lost 0.2±3.1 kg (0.4±6.8 lb). Further, participants with MS in the OLM group who completed the study experienced a 3.1±3.9 kg/m2 decrease in BMI whereas participants with MS in the WLC group only experienced a 0.1±1.2 kg/m2 decrease in BMI. No changes in other MS risk factors were significant. Conclusions: Patients with MS experienced significant weight loss and decreases in BMI as a result of a lifestyle and pharmacotherapy intervention.
Key wordsMetabolic syndrome orlistat obesity insulin resistance weight loss
- 2.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486–2497, 2001.CrossRefGoogle Scholar
- 4.National Institutes of Health: Physical Activity and Cardiovascular Health. NIH Consensus Statement, 13, 1–33, 1995.Google Scholar
- 7.Poppitt S.D., Keogh G.F., Prentice A.M., Williams D.E., Sonnemans H.M., Valk E.E., Robinson E., Wareham N.J.: Long-term effects of ad libitum low-fat, high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. Am. J. Clin. Nutr., 75, 11–20, 2002.PubMedGoogle Scholar
- 8.Metabolic Syndrome by the American Heart Association. (2002). Retrieved February 4, 2004, from http://www.americanheart.org/presenter.jhtml?identifier=4756.
- 10.Fujioka K., Pirner M.A., Hewkin A., Renz C.L.: Effects of sibutramine-induced weight loss on patients with metabolic syndrome. Obes. Res., 11, A110, 2003.Google Scholar
- 18.Davidson M., Hauptman J., DiGirolamo M., Foreyt J.P., Halsted C.H., Herber D., Heimburger D.C., Lucas C.P., Robbins D.C., Chung J., Heymsfield S.B.: Weight control and risk factor reduction obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA, 281, 235–242, 1999.PubMedCrossRefGoogle Scholar
- 20.Sjostrom L., Rissanen A., Andersen T., Boldrin M., Golay A., Koppeschaar H.P., Krempf M. for the European Multicenter Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 352, 167–172, 1998.PubMedCrossRefGoogle Scholar
- 23.Poston W.S.C., Reeves R.S., Haddock C.K., Stormer S., Balasubramanyam A., Satterwhite O., Taylor J.E., Foreyt J.P.: Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int. J. Obes. Relat. Metab. Disord., 27, 1486–1493, 2003.PubMedCrossRefGoogle Scholar